{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:17:48Z","timestamp":1792649868926,"version":"4.5.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81872480"],"award-info":[{"award-number":["81872480"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81760549"],"award-info":[{"award-number":["81760549"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81560492"],"award-info":[{"award-number":["81560492"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Accumulating pre-clinical and clinical studies suggested that the renin\u2013angiotensin system blockers (RASBs) possess anti-carcinogenic properties, and their use is associated with favorable outcomes in many types of cancers.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A systematic literature search of relevant databases through January 2019 was conducted to identify studies assessing the RASBs on prognostic outcomes in digestive system malignancies patients on the basis of predetermined selection criteria for pooled hazard ratio (HR) with 95% confidence intervals (CIs). A total of 13 studies were included in the meta-analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The meta-analysis showed that the use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) resulted in a significant improvement in overall survival (HR 0.79; 95%CI 0.70\u20130.89; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.000), cancer-specific survival (HR 0.81; 95%CI 0.73\u20130.90; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.000) and recurrence-free survival (HR 0.68; 95%CI 0.54\u20130.85; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.001), but not progression-free survival (HR 0.88; 95%CI 0.73\u20131.07; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.183) and disease-free survival (HR 0.50; 95%CI 0.11\u20132.39; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.103). Subgroup analysis indicated that the use of RASBs has a significant improvement of overall survival (OS) in pancreatic cancer, liver cancer, and gastric cancer. Two studies evaluated the dose\u2013response relationship between ACEIs\/ARBs therapy and survival and showed higher doses and better survival [(1\u2013364 defined daily doses: odds ratio (OR) 0.89, 95%CI 0.78\u20131.01, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.076), (\u2265365 defined daily doses: OR 0.54, 95%CI: 0.24\u20131.24, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.148].<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Meta-analysis of studies supports a beneficial association between use of RASBs and survival of digestive system malignancies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000019075","type":"journal-article","created":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T20:10:43Z","timestamp":1581538243000},"page":"e19075","source":"Crossref","is-referenced-by-count":22,"title":["The renin\u2013angiotensin system blockers and survival in digestive system malignancies"],"prefix":"10.1097","volume":"99","author":[{"given":"Qi","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di-Shi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Daye People's Hospital, Daye, Hubei Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Xin","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Qiang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hou-Ting","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Wu","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Hao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,2]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme","volume":"362","author":"Pfeffer","year":"2003","journal-title":"The Lancet"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/hr.2011.213","article-title":"The C718T polymorphism in the 3\u2032-untranslated region of glutathione peroxidase-4 gene is a predictor of cerebral stroke in patients with essential hypertension","volume":"35","author":"Polonikov","year":"2012","journal-title":"Hypertens Res"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahl\u00f6f","year":"2002","journal-title":"The Lancet"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/eurheartj\/ehq382","article-title":"Twisting arms to angiotensin receptor blockers\/antagonists: the turn of cancer","volume":"32","author":"Volpe","year":"2011","journal-title":"Eur Heart J"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nrc2945","article-title":"The renin\u2013angiotensin system and cancer: old dog, new tricks","volume":"10","author":"George","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"R7-20230915","article-title":"Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth","volume":"112","author":"Kimiyasu","year":"2003","journal-title":"J Clin Invest"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1093\/carcin\/bgn171","article-title":"The renin\u2013angiotensin system and malignancy","volume":"29","author":"Ager","year":"2008","journal-title":"Carcinogenesis"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1096\/fj.03-0129com","article-title":"Differential regulation of in vivo angiogenesis by angiotensin II receptors","volume":"17","author":"Walther","year":"2003","journal-title":"FASEB J"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(10)70260-6","article-title":"Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials","volume":"12","author":"Bangalore","year":"2011","journal-title":"Lancet Oncol"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.amjcard.2011.03.038","article-title":"Meta-analysis of randomized controlled trials on effect of angiotensin-converting enzyme inhibitors on cancer risk","volume":"108","author":"Sipahi","year":"2011","journal-title":"Am J Cardiol"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s10552-015-0617-1","article-title":"Angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers therapy and colorectal cancer: a systematic review and meta-analysis","volume":"26","author":"Dai","year":"2015","journal-title":"Cancer Causes Control"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/ijc.30062","article-title":"Use of beta-blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: systematic review and meta-analysis","volume":"139","author":"Raimondi","year":"2016","journal-title":"Int J Cancer"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10552-011-9881-x","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review","volume":"23","author":"Mc Menamin","year":"2012","journal-title":"Cancer Causes Control"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistic to perform meta-analysis of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Stat Med"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1186\/1741-7015-12-28","article-title":"Drugs affecting the renin\u2013angiotensin system and survival from cancer: a population based study of breast, colorectal and prostate cancer patient cohorts","volume":"12","author":"Cardwell","year":"2014","journal-title":"BMC Med"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/apt.14388","article-title":"Angiotensin receptor blocker use and gastro-oesophageal cancer survival: a population-based cohort study","volume":"47","author":"Busby","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1998","journal-title":"BMJ"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1007\/s00268-017-4021-8","article-title":"Impact of angiotensin receptor blocker use on overall survival among patients undergoing resection for pancreatic cancer","volume":"41","author":"Cerullo","year":"2017","journal-title":"World J Surg"},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1177\/1470320314535275","article-title":"Prognostic impact of renin\u2013angiotensin system blockade in esophageal squamous cell carcinoma","volume":"16","author":"Chen","year":"2015","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1593\/tlo.13346","article-title":"Exposure to ACEI\/ARB and \u03b2-blockers is associated with improved survival and decreased tumor progression and hospitalizations in patients with advanced colon cancer","volume":"6","author":"Engineer","year":"2013","journal-title":"Transl Oncol"},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1111\/jgh.12988","article-title":"Angiotensin receptor blockers improve survival outcomes after radiofrequency ablation in hepatocarcinoma patients","volume":"30","author":"Facciorusso","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"R23-20230915","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1177\/000313480707300307","article-title":"Predictors of distant metastasis and mortality in patients with stage II colorectal cancer","volume":"73","author":"Heinzerling","year":"2007","journal-title":"Am Surg"},{"key":"R24-20230915","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.canep.2013.09.001","article-title":"Antihypertensive medications and survival in patients with cancer: a population-based retrospective cohort study","volume":"37","author":"Holmes","year":"2013","journal-title":"Cancer Epidemiol"},{"key":"R25-20230915","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000337979","article-title":"How does inhibition of the renin\u2013angiotensin system affect the prognosis of advanced gastric cancer patients receiving platinum-based chemotherapy?","volume":"83","author":"Kim","year":"2012","journal-title":"Oncology"},{"key":"R26-20230915","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1002\/cncr.30079","article-title":"Increased tumor response to neoadjuvant therapy among rectal cancer patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers","volume":"122","author":"Morris","year":"2016","journal-title":"Cancer"},{"key":"R27-20230915","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1038\/sj.bjc.6605955","article-title":"Inhibition of renin\u2013angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine","volume":"103","author":"Nakai","year":"2010","journal-title":"Br J Cancer"},{"key":"R28-20230915","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00432-014-1873-2","article-title":"The inhibition of renin\u2013angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients","volume":"141","author":"Nakai","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"R29-20230915","first-page":"1547","volume":"26","author":"Yoshiji","year":"2011","journal-title":"Combination of branched-chain amino acids and angiotensin converting enzyme inhibitor suppresses the cumulative recurrence of hepatocellular carcinoma: a randomized control trial Oncology Reports"},{"key":"R30-20230915","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2174\/187152506777698326","article-title":"Blockade of the renin\u2013angiotensin\u2013aldosterone system: effects on hypertensive target organ damage","volume":"4","author":"Grandi","year":"2006","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"R31-20230915","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1503\/cmaj.101497","article-title":"Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta-analysis of observational studies","volume":"183","author":"Yoon","year":"2011","journal-title":"Can Med Assoc J"},{"key":"R32-20230915","doi-asserted-by":"crossref","first-page":"e3600","DOI":"10.1097\/MD.0000000000003600","article-title":"Angiotensin II receptor blockers and cancer risk: a meta-analysis of randomized controlled trials","volume":"95","author":"Zhao","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"R33-20230915","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1080\/02841860310022346","article-title":"Angiotensin converting enzyme inhibitors for cancer treatment?","volume":"43","author":"Lindberg","year":"2004","journal-title":"Acta Oncol"},{"key":"R34-20230915","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1349-7006.2000.tb00940.x","article-title":"Tumor-selective blood flow decrease induced by an angiotensin converting enzyme inhibitor, temocapril hydrochloride","volume":"91","author":"Hori","year":"2000","journal-title":"Jpn J Cancer Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000019075","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T23:07:08Z","timestamp":1694819228000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000019075"}},"subtitle":["A systematic review and meta-analysis"],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":34,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000019075","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2]]}}}